Robin Atallah, Elmer Rutjes, Jan P M Frölke, Ruud A Leijendekkers
{"title":"Safety and performance of contemporary press-fit titanium osseointegration implants in lower extremity amputation : a five-year follow-up study.","authors":"Robin Atallah, Elmer Rutjes, Jan P M Frölke, Ruud A Leijendekkers","doi":"10.1302/0301-620X.107B4.BJJ-2024-0754.R1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Treatment using bone-anchored prostheses (BAPs) with press-fit femoral osseointegration implants (OIs) has been used in patients with lower limb amputations for more than two decades. The development of these OIs has enabled treatment in patients with a short transfemoral and a transtibial amputation. The aim of this follow-up study was to report the safety of this treatment at five years postoperatively, the prosthesis wearing time (PWT), and health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>All consecutive patients undergoing treatment between March 2015 and June 2018 using one of three different OIs were eligible for inclusion. A total of 90 patients were included, of whom 14 were lost to follow-up, leaving 76 available for analysis. The curved- or gamma-osseointegration femoral implant (OFI-C, OFI-Y) was used in patients with a mid-diaphyseal or short transfemoral amputation, respectively. The osseointegration tibial implant (OTI) was used in those with a transtibial amputation. The adverse events which were evaluated included infection (soft-tissue, bone, implant), stoma-related complications, aseptic loosening, implant breakage, periprosthetic fracture, and complications between surgical stages. The functional outcomes which were assessed included the Questionnaire for Persons with a Transfemoral Amputation (Q-TFA)-Prosthetic Use Score (PUS) and the Global Score (GS), for PWT and HRQoL, respectively.</p><p><strong>Results: </strong>A 94.2% implant survival was achieved at five years (OFI-C = 93.8%, OFI-Y = 93.3%, OTI = 95.5%); five implants were removed. Overall, 27 patients (36%) had a total of 56 infections, 53 (95%) of which were infections of the soft-tissues. Septic loosening occurred in three patients (4%, OFI-C = 2, OTI = 1), resulting in removal of the implant in two. The infection/implant-year ratio was 0.09, 0.16, and 0.24 for OFI-C, OFI-Y and OTI, respectively. Periprosthetic fracture occurred in four patients (5%, all OFI-C); all were treated surgically, three with fixation, one with removal. One patient had asymptomatic radiological evidence of partial aseptic loosening; this was managed conservatively. Stoma-related problems required surgery on 26 occasions, mostly in patients treated with an OFI-Y. The implant was removed in two patients (2.6%) due to unexplained pain. Complications between surgical stages were mostly surgical site infections, requiring bringing forward stage 2 on seven occasions. Baseline Q-TFA-PUS and GS scores increased significantly in all patients, and also when stratified per type of implant with the passage of time.</p><p><strong>Conclusion: </strong>Contemporary press-fit titanium OIs, when used in lower limb amputations, result in acceptable rates of survival and safety, with considerable improvements in functional outcomes.</p>","PeriodicalId":48944,"journal":{"name":"Bone & Joint Journal","volume":"107-B 4","pages":"486-494"},"PeriodicalIF":4.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone & Joint Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1302/0301-620X.107B4.BJJ-2024-0754.R1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Treatment using bone-anchored prostheses (BAPs) with press-fit femoral osseointegration implants (OIs) has been used in patients with lower limb amputations for more than two decades. The development of these OIs has enabled treatment in patients with a short transfemoral and a transtibial amputation. The aim of this follow-up study was to report the safety of this treatment at five years postoperatively, the prosthesis wearing time (PWT), and health-related quality of life (HRQoL).
Methods: All consecutive patients undergoing treatment between March 2015 and June 2018 using one of three different OIs were eligible for inclusion. A total of 90 patients were included, of whom 14 were lost to follow-up, leaving 76 available for analysis. The curved- or gamma-osseointegration femoral implant (OFI-C, OFI-Y) was used in patients with a mid-diaphyseal or short transfemoral amputation, respectively. The osseointegration tibial implant (OTI) was used in those with a transtibial amputation. The adverse events which were evaluated included infection (soft-tissue, bone, implant), stoma-related complications, aseptic loosening, implant breakage, periprosthetic fracture, and complications between surgical stages. The functional outcomes which were assessed included the Questionnaire for Persons with a Transfemoral Amputation (Q-TFA)-Prosthetic Use Score (PUS) and the Global Score (GS), for PWT and HRQoL, respectively.
Results: A 94.2% implant survival was achieved at five years (OFI-C = 93.8%, OFI-Y = 93.3%, OTI = 95.5%); five implants were removed. Overall, 27 patients (36%) had a total of 56 infections, 53 (95%) of which were infections of the soft-tissues. Septic loosening occurred in three patients (4%, OFI-C = 2, OTI = 1), resulting in removal of the implant in two. The infection/implant-year ratio was 0.09, 0.16, and 0.24 for OFI-C, OFI-Y and OTI, respectively. Periprosthetic fracture occurred in four patients (5%, all OFI-C); all were treated surgically, three with fixation, one with removal. One patient had asymptomatic radiological evidence of partial aseptic loosening; this was managed conservatively. Stoma-related problems required surgery on 26 occasions, mostly in patients treated with an OFI-Y. The implant was removed in two patients (2.6%) due to unexplained pain. Complications between surgical stages were mostly surgical site infections, requiring bringing forward stage 2 on seven occasions. Baseline Q-TFA-PUS and GS scores increased significantly in all patients, and also when stratified per type of implant with the passage of time.
Conclusion: Contemporary press-fit titanium OIs, when used in lower limb amputations, result in acceptable rates of survival and safety, with considerable improvements in functional outcomes.
期刊介绍:
We welcome original articles from any part of the world. The papers are assessed by members of the Editorial Board and our international panel of expert reviewers, then either accepted for publication or rejected by the Editor. We receive over 2000 submissions each year and accept about 250 for publication, many after revisions recommended by the reviewers, editors or statistical advisers. A decision usually takes between six and eight weeks. Each paper is assessed by two reviewers with a special interest in the subject covered by the paper, and also by members of the editorial team. Controversial papers will be discussed at a full meeting of the Editorial Board. Publication is between four and six months after acceptance.